NCT02614495View on ClinicalTrials.gov

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 24, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Thyroid Carcinoma
Interventions
DRUG

Surufatinib

Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)

Trial Locations (2)

100032

Peking Union Medical College Hospital, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02614495 - Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | Biotech Hunter | Biotech Hunter